+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Atopic Dermatitis Drugs Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable ROA, Oral ROA, Tropical ROA) - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • January 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904629
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Atopic Dermatitis Drugs Market size was estimated at USD 8.02 billion in 2023, USD 8.56 billion in 2024, and is expected to grow at a CAGR of 6.84% to reach USD 12.76 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Atopic Dermatitis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atopic Dermatitis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Biologics
    • Calcineurin Inhibitors
    • Corticosteroids
    • Phosphodiesterases 4 Inhibitors
  • Route of Administration
    • Injectable ROA
    • Oral ROA
    • Tropical ROA
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Atopic Dermatitis Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atopic Dermatitis Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Atopic Dermatitis Drugs Market?
  4. What is the market share of the leading vendors in the Atopic Dermatitis Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Atopic Dermatitis Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Frequently Asked Questions about the Global Atopic Dermatitis Drugs Market

What is the estimated value of the Global Atopic Dermatitis Drugs Market?

The Global Atopic Dermatitis Drugs Market was estimated to be valued at $8.56 Billion in 2024.

What is the growth rate of the Global Atopic Dermatitis Drugs Market?

The growth rate of the Global Atopic Dermatitis Drugs Market is 6.8%, with an estimated value of $12.76 Billion by 2030.

What is the forecasted size of the Global Atopic Dermatitis Drugs Market?

The Global Atopic Dermatitis Drugs Market is estimated to be worth $12.76 Billion by 2030.

Who are the key companies in the Global Atopic Dermatitis Drugs Market?

Key companies in the Global Atopic Dermatitis Drugs Market include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol, Myers Squibb Company, Eli Lilly and Company, F. Hoffmann, La Roche Ltd. and Galderma S.A..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Atopic Dermatitis Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of atopic dermatitis
5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
5.1.2. Restraints
5.1.2.1. High cost of therapeutics
5.1.3. Opportunities
5.1.3.1. Rising awareness regarding the availability of treatments for the disease
5.1.3.2. Growing access to treatment in various developing countries
5.1.4. Challenges
5.1.4.1. Adverse effects associated with the use of medication
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Atopic Dermatitis Drugs Market, by Drug Class
6.1. Introduction
6.2. Biologics
6.3. Calcineurin Inhibitors
6.4. Corticosteroids
6.5. Phosphodiesterases 4 Inhibitors
7. Atopic Dermatitis Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable ROA
7.3. Oral ROA
7.4. Tropical ROA
8. Americas Atopic Dermatitis Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Atopic Dermatitis Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Bausch Health Companies Inc.
12.1.3. Bayer AG
12.1.4. Biofrontera AG
12.1.5. Bristol-Myers Squibb Company
12.1.6. Eli Lilly and Company
12.1.7. F. Hoffmann-La Roche Ltd.
12.1.8. Galderma S.A.
12.1.9. GlaxoSmithKline PLC
12.1.10. LEO Pharma A/S
12.1.11. Meda AB
12.1.12. Mylan N.V.
12.1.13. Novartis AG
12.1.14. Pfizer Inc.
12.1.15. Regeneron Pharmaceuticals, Inc
12.1.16. Sanofi S.A.
12.1.17. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. ATOPIC DERMATITIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ATOPIC DERMATITIS DRUGS MARKET DYNAMICS
FIGURE 7. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ATOPIC DERMATITIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PHOSPHODIESTERASES 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 101. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 102. ATOPIC DERMATITIS DRUGS MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma S.A.
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
  • Meda AB
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...